Publications by authors named "Kerstin Luhn"

Claim this Profile
H
Heterologous two-dose Ebola vaccine regimen in pregnant women in Rwanda: a randomized controlled phase 3 trial.
Julien Nyombayire, Rosine Ingabire, Amelia Mazzei, Tyronza Sharkey, Claudine Umuhoza, Kerstin Luhn

Nat Med· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ebola virus vaccination elicits Ebola virus-specific immune responses without substantial cross-reactivity to other filoviruses.
Thembi Mdluli, Suzanne Wollen-Roberts, Mélanie Merbah, Bradley Beckman, Yifan Li, Kerstin Luhn

Sci Transl Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Innate and Cellular Immune Response to the Ebola Vaccine Ad26.ZEBOV, MVA-BN-Filo: An Ancillary Study of the EBL2001 Phase 2 Trial.
Christine Lacabaratz, Mélany Durand, Aurélie Wiedemann, Emile Foucat, Mathieu Surénaud, Kerstin Luhn

J Infect Dis· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial.
Neil Goldstein, Chelsea McLean, Auguste Gaddah, Joachim Doua, Babajide Keshinro, Kerstin Luhn

Hum Vaccin Immunother· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of antibodies against platelet factor 4 following vaccination with adenovirus type 26-vectored vaccines.
Hendy Kristyanto, Leen Slaets, Esmée Braams, Ilse Scheys, Roy Heesbeen

J Thromb Haemost· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Immunogenicity of Accelerated Heterologous 2-Dose Ebola Vaccine Regimens in Adults With and Without HIV in Africa.
Betty Mwesigwa, Fredrick Sawe, Janet Oyieko, Joel Mwakisisile, Edna Viegas, Kerstin Luhn

Clin Infect Dis· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Computational mining of B cell receptor repertoires reveals antigen-specific and convergent responses to Ebola vaccination.
Eve Richardson, Sagida Bibi, Florence McLean, Lisa Schimanski, Pramila Rijal, Kerstin Luhn

Front Immunol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity of an Extended Dose Interval for the Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children in the Democratic Republic of the Congo.
Edward Man-Lik Choi, Kambale Kasonia, Hugo Kavunga-Membo, Daniel Mukadi-Bamuleka, Aboubacar Soumah, Kerstin Luhn

Vaccines (Basel)· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Immunogenicity of an Accelerated Ebola Vaccination Schedule in People with and without Human Immunodeficiency Virus: A Randomized Clinical Trial.
Julie A Ake, Kristopher Paolino, Jack N Hutter, Susan Biggs Cicatelli, Leigh Anne Eller, Kerstin Luhn

Vaccines (Basel)· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Clinical Safety of the Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: A Prospective, Multi-Country, Observational Study.
Adeep Puri, Andrew J Pollard, Catherine Schmidt-Mutter, Fabrice Lainé, George PrayGod, Kerstin Luhn

Vaccines (Basel)· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda.
Edward Man-Lik Choi, Ggayi Abu-Baker Mustapher, Gloria Omosa-Manyonyi, Julie Foster, Zacchaeus Anywaine, Kerstin Luhn

Vaccine· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone.
Edward Man-Lik Choi, Boris Lacarra, Muhammed O Afolabi, Boni Maxime Ale, Frank Baiden, Kerstin Luhn

Lancet Glob Health· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of early gene expression profiles associated with long-lasting antibody responses to the Ebola vaccine Ad26.ZEBOV/MVA-BN-Filo.
Fabiola Blengio, Hakim Hocini, Laura Richert, Cécile Lefebvre, Mélany Durand, Kerstin Luhn

Cell Rep· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans.
Chelsea McLean, Karin Dijkman, Auguste Gaddah, Babajide Keshinro, Michael Katwere, Kerstin Luhn

Front Immunol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune response of a two-dose heterologous Ebola vaccine regimen: summary of three African clinical trials using a single validated Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay in a single accredited laboratory.
Chelsea McLean, Houreratou Barry, Mark Kieh, Zacchaeus Anywaine, Baimba Tapima Rogers, Kerstin Luhn

EBioMedicine· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial.
Daniela Manno, Agnes Bangura, Frank Baiden, Abu Bakarr Kamara, Philip Ayieko, Kerstin Luhn

Lancet Infect Dis· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola.
Viki Bockstal, Maarten Leyssen, Dirk Heerwegh, Bart Spiessens, Cynthia Robinson, Kerstin Luhn

NPJ Vaccines· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study.
Viki Bockstal, Georgi Shukarev, Chelsea McLean, Neil Goldstein, Stephan Bart, Kerstin Luhn

PLoS One· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An introduction to the Marburg virus vaccine consortium, MARVAC.
Robert W Cross, Ira M Longini, Stephan Becker, Karin Bok, David Boucher, Kerstin Luhn

PLoS Pathog· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protection against Marburg Virus and Sudan Virus in NHP by an Adenovector-Based Trivalent Vaccine Regimen Is Correlated to Humoral Immune Response Levels.
Machteld M Tiemessen, Laura Solforosi, Liesbeth Dekking, Dominika Czapska-Casey, Jan Serroyen, Kerstin Luhn

Vaccines (Basel)· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NK Cell Subset Redistribution and Antibody Dependent Activation after Ebola Vaccination in Africans.
Helen R Wagstaffe, Omu Anzala, Hannah Kibuuka, Zacchaeus Anywaine, Sodiomon B Sirima, Kerstin Luhn

Vaccines (Basel)· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo.
Deborah Watson-Jones, Hugo Kavunga-Membo, Rebecca F Grais, Steve Ahuka, Natalie Roberts, Kerstin Luhn

BMJ Open· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial.
Zacchaeus Anywaine, Houreratou Barry, Omu Anzala, Gaudensia Mutua, Sodiomon B Sirima, Kerstin Luhn

PLoS Med· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen.
Viki Bockstal, Auguste Gaddah, Neil Goldstein, Georgi Shukarev, Stephan Bart, Kerstin Luhn

NPJ Vaccines· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa.
Houreratou Barry, Gaudensia Mutua, Hannah Kibuuka, Zacchaeus Anywaine, Sodiomon B Sirima, Kerstin Luhn

PLoS Med· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis